Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical variables and serum protein biomarkers

Louise C. LAURENT, MD, PhD[1*], George R. SAADE, MD[2], Glenn R. MARKENSON, MD[3], Kent D. HEYBORNE, MD[4], Corina N. SCHOEN, MD[5], Jason K. BAXTER, MD[6], Sherri A. LONGO, MD[7], Leonardo M. PEREIRA, MD[8], Emily J. SU, MD[9], Matthew K. HOFFMAN, MD[10], Garrett K. LAM, MD[11], Angela C. FOX, MS[12], Ashoka D. POLPITIYA, D Sc[12], Md. Bahadur BADSHA, PhD[12], Tracey C. FLEISCHER, PhD[12], Thomas J. GARITE, MD[12], J. Jay BONIFACE, PhD[12], Paul E. KEARNEY, PhD[12]

[1]Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, La Jolla, CA

[2]Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA

[3]Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA

[4]Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO, and Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, CO

[5]Department of Obstetrics and Gynecology, University of Massachusetts-Baystate, Springfield, MA

[6]Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

[7]Department of Obstetrics and Gynecology, Ochsner Health, New Orleans, LA

[8]Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR

[9]Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO

[10]Department of Obstetrics and Gynecology, ChristianaCare Health System, Wilmington DE

[11]Regional Obstetrical Consultants, Chattanooga, TN; Department of Obstetrics & Gynecology, University of Tennessee Health Science Center and College of Medicine, Chattanooga, TN

[12]Sera Prognostics, Inc., Salt Lake City, UT

Conflict of Interest Statement

ACF, MBB, TCF, TJG, JJB, and PEK are employees of Sera Prognostics, Inc., and receive salary and stock options. ADP is a paid consultant to Sera Prognostics, Inc. GKL was an employee of Sera Prognostics, Inc., but not during the research period for these analyses, nor during manuscript construction and publication. MKH received an Investigator Initiated Grant from Sera Prognostics, Inc., to investigate preterm birth risk stratification and treatment. The remaining authors report no conflict of interest.

Source of Funding

Sponsorship of the trial was provided by Sera Prognostics, Inc. The sponsor funded the study, generated biomarker data and discovered and blindly validated the predictors.

***Corresponding Author**

Louise C. LAURENT, MD, PhD

Professor and Vice-Chair for Clinical and Translational Research

University of California, San Diego

Department of Obstetrics, Gynecology, and Reproductive Sciences

Division of Maternal Fetal Medicine

The Sanford Consortium for Regenerative Medicine

2880 Torrey Pines Scenic Dr.

La Jolla, CA 92037-0695

Phone: 858-246-1405

FAX: 858-534-8329

llaurent@ucsd.edu

Word Count

Abstract: 395

Main Text: 3000

Condensation

Novel, high-performing predictors of preterm preeclampsia risk comprised of proteomic biomarkers with a composite clinical variable.

Short title

Proteomic biomarker risk predictors for preterm preeclampsia

Conflict of Interest Statement

ACF, MBB, TCF, TJG, JJB, and PEK are employees of Sera Prognostics, Inc., and receive salary and stock options. ADP is a paid consultant to Sera Prognostics, Inc. GKL was an employee of Sera Prognostics, Inc., but not during the research period for these analyses, nor during manuscript construction and publication. MKH received an Investigator Initiated Grant from Sera Prognostics, Inc., to investigate preterm birth risk stratification and treatment. The other authors have no conflict of interest to declare.

Source of Funding

Sponsorship of the trial was provided by Sera Prognostics, Inc. The sponsor funded the study, generated biomarker data and discovered and blindly validated the predictors.

73 **Keywords**

74 Preeclampsia, preterm preeclampsia, protein biomarker risk predictor, hypertension, diabetes

Abstract

Background: Preeclampsia is associated with poor maternal and fetal outcomes. Preeclampsia diagnosed prior to 37 weeks' gestational age (preterm preeclampsia) is more likely than term preeclampsia to give rise to serious morbidities and complicate clinical decision making. Clinical risk factors for preeclampsia, including preeclampsia in a previous pregnancy, chronic hypertension, and diabetes, do not provide adequate predictive value. There remains an urgent need to develop an accurate and practical risk predictor for preterm preeclampsia – particularly early preterm PE (gestational age at delivery <34 weeks) – to help guide clinical management.

Objective(s): The objective of this study was to discover, verify, and validate mid-trimester preterm PE predictors that employ both relevant clinical factors and maternal serum analytes.

Study Design: This was a secondary analysis of data from two large, multicenter studies (PAPR, NCT01371019; TREETOP, NCT02787213). Eligible subjects had gestational ages at blood draw of $18^{0/7}$-$22^{6/7}$ weeks (PAPR) and $18^{0/7}$-$20^{6/7}$weeks (TREETOP). PAPR subjects were assigned to a discovery cohort (n=1352), and TREETOP subjects were randomly assigned to either a verification cohort (n=1217) or a validation cohort (n=2289). Peptides were analyzed by liquid chromatography-multiple reaction monitoring mass spectrometry measuring pregnancy-related and quality control proteins. Classifier models combined one novel protein ratio with a composite clinical variable (Clin3, which was scored positive if any of these was true: PE in a previous pregnancy; pre-existing hypertension; or pregestational diabetes). Classifier performance was assessed via area under the receiver operating characteristic curve at various gestational age at delivery cutoffs and threshold-based performance metrics. Threshold-based performance was also assessed in a validation cohort subset that had more accurate gestational age dating via early ultrasound.

Results: Nine of nine prespecified classifier models were validated for preterm preeclampsia, with areas under the receiver operating characteristic curve ranging from 0.72-0.78 for PE with delivery <37 weeks. Each exhibited greater predictive performance than did Clin3 alone (0.68). Under this condition, one exemplified predictor, Clin3 + inhibin subunit beta C chain/sex hormone binding globulin, showed 76% sensitivity for preterm PE prediction and 89% for early preterm PE (GAD <34 weeks), both at 75% specificity.

Conclusion(s): A proteomic approach identified a profile predictive of preeclampsia that was validated in an independent cohort as more predictive than clinical risk factors alone. This single blood test, performed in the first half of pregnancy, may be the basis for future clinical intervention approaches to prevent preeclampsia and improve maternal and perinatal outcomes.

111 **Introduction**

112 Preeclampsia (PE) occurs in 5-7% of pregnancies[1,2] and is implicated in 14% of maternal[3] and 10-25% of
113 perinatal[4,5] deaths. It is associated with ~25% of all preterm births (PTB) and 50% of medically indicated
114 PTBs.[6] The only cure for PE is delivery, with other therapies focused on preventing or delaying onset
115 (low-dose aspirin [LDASA]),[7-9] preventing end-organ damage (antihypertensive medications to prevent
116 strokes[10] and magnesium sulfate to prevent seizures),[8] and decreasing neonatal complications from
117 prematurity (antenatal steroids).[8] Because PE-associated perinatal morbidity and mortality and
118 healthcare costs correlate with prematurity,[11-13] accurate prediction of preterm PE (gestational age [GA]
119 at delivery [GAD] <37 weeks), and particularly early preterm PE (GAD <34 weeks), holds greater clinical
120 and economic value than does prediction of late preterm PE with GAD 34-37 weeks.

121 Until recently, PE prediction relied largely on clinical risk factors, including: PE in a previous
122 pregnancy; high body mass index (BMI); maternal chronic hypertension, diabetes, renal disease, and
123 autoimmune conditions; and obstetrical characteristics such as multiple gestation and use of assisted
124 reproductive technologies.[8] Analysis of a Danish cohort of 597,492 pregnancies[14] showed that the
125 clinical factors listed in National Institute of Health and Care Excellence (NICE) guidelines[15] would have
126 predicted 47% of PE cases (at any GA) at a screen-positive rate (SPR) of 8.1% and a positive predictive
127 value (PPV) of 5.4%, while those in American College of Obstetricians and Gynecologists (ACOG)
128 criteria[16] would have predicted 60.5% of PE cases at an SPR of 18.2% and a PPV of 5.6%. PE and
129 gestational hypertension in a previous pregnancy are among the most predictive and commonly used
130 risk factors but are irrelevant to nulliparous pregnancies. A predictor with adequate PPV could guide
131 appropriate LDASA prophylaxis and surveillance of higher-risk cases, while a predictor with a high
132 negative predictive value (NPV) (e.g., >99%) could identify lower-risk patients who might safely forgo or
133 discontinue interventions.

134 Numerous PE-associated molecular biomarkers have been reported,[17-29] including soluble fms-
135 like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF). In patients with clinically suspected PE,
136 sFlt-1 and PlGF enable earlier diagnosis and/or modestly decrease adverse maternal outcomes.[30-33]
137 However, they do not adequately predict PE in pre-symptomatic pregnancies, which is a substantial
138 limitation, as LDASA is most effective when initiated early in pregnancy.[34] Pre-symptomatic prediction
139 strategies incorporating combinations of serum analytes, patient history, blood pressure, and uterine
140 artery pulsatility index are accurate but not widely used, as they require sophisticated equipment with
141 highly trained sonographers along with molecular analyses.[35-38] Also, studies of these predictors have
142 focused on late-onset PE; included only cases conforming to classical definitions; or grouped PE cases
143 across all GAs and/or severities together. PE is highly heterogeneous[39-42] and at minimum should be
144 divided into early- and late-onset cases[11,43,44] in biomarker studies to enable separate predictive
145 performance assessments.
146 There is an urgent need for accurate, safe, and practical preterm PE risk predictors that can be
147 employed early in gestation to guide clinical management. This study aimed to develop a mid-trimester
148 predictor comprising molecular biomarkers and relevant clinical factors, with validation across
149 demographically, geographically, and temporally diverse populations.
150

151 **Materials and Methods**

152 *Study design*

153 Biomarker development was based on U.S. National Academy of Medicine guidelines.[45] This was a
154 secondary analysis using data from two large, multicenter U.S. cohort studies to discover, verify, and
155 validate risk predictors for preterm PE. The Proteomic Assessment of Preterm Risk (PAPR,
156 NCT01371019)[46] and the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor
157 (TREETOP, NCT02787213)[47] studies were prospective, observational studies aimed at developing a

158 proteomic biomarker for PTB risk stratification. Study approvals were provided by site IRBs, and
159 participants provided written informed consent.
160
161 *Participants*
162 PAPR and TREETOP enrolled gravidas ≥18 years of age with singleton pregnancies from $17^{0/7}$-$28^{6/7}$ or
163 $17^{0/7}$-$21^{6/7}$ weeks' gestation, respectively, and excluded pregnancies with planned delivery <$37^{0/7}$ weeks'
164 gestation, major anomalies or chromosomal disorders, or planned cervical cerclage. GA was determined
165 according to ACOG criteria[48,49]. In TREETOP, progesterone use >$13^{6/7}$ weeks' gestation was an exclusion
166 criterion. Demographic, medical and pregnancy history, medication, and post-delivery maternal and
167 infant outcome information was collected. Adjudication of PE and PTB cases was blinded, occurring prior
168 to database lockdown and analyses.
169
170 *Selection of cases and controls*
171 Discovery was performed in a PAPR-derived cohort that was distinct from the TREETOP-derived
172 verification and validation cohorts (**Figure 1**). The discovery and verification/validation cohorts included
173 blood samples drawn $18^{0/7}$-$22^{6/7}$ and $18^{0/7}$-$20^{6/7}$ weeks' gestation, respectively. The discovery cohort
174 used a broader GA at blood draw (GABD) window to increase sample size. TREETOP subjects were
175 randomly assigned by an independent third-party statistician to blinded verification (one-third) or
176 validation (two-thirds) cohorts.[47] The validation cohort included four sites and six months of enrollment
177 not represented in the verification cohort.
178 Candidate classifier features were ascertained in discovery, with parameters confirmed and
179 tuned in verification to account for temporal changes in care and population. Cases were defined as
180 subjects with PE who delivered <37 weeks' gestation; controls were defined as noncases.

181 Prespecified classifier models were validated by a third-party statistician. Each classifier was
182 validated using AUC, then by *P*-value, for three score thresholds distinguishing higher from lower risk.
183 Thresholds were predefined based on discovery performance to allow for sensitivity and specificity
184 tradeoffs and to enable use in varied clinical settings. Better estimation of test performance is obtained
185 in more precisely GA-dated individuals,[50] and crown-rump length is more precise when determined prior
186 to $9^{0/7}$ weeks' gestation.[49] Thus, following validation on the full cohort, post-validation performance was
187 assessed on a sub-cohort comprising subjects dated by ultrasound prior to $9^{0/7}$-weeks' gestation (early
188 GA dating). Performance metrics were calculated for GA cutoffs of <37, <34, and <32 weeks in all
189 subjects and <37 and <34 weeks in nulliparas, for whom low case numbers precluded a <32-week
190 performance calculation. Performance was measured without gapping;[50] i.e., controls included subjects
191 delivering before GA cutoffs without a PE diagnosis plus subjects delivering after the cutoffs, including
192 those with PE. This ensured applicability of classifiers across the intended use population while avoiding
193 gapping-associated predictive performance inflation.[50]
194
195 *Sample processing*
196 Maternal blood was collected, processed and stored as described previously.[46,47]Serum samples were
197 depleted of abundant proteins, reduced, alkylated, and digested with trypsin. Stable isotope standard
198 (SIS) peptides were added post-digest, and peptides were analyzed by a liquid chromatography-multiple
199 reaction monitoring mass spectrometry assay measuring quality control and pregnancy-related
200 proteins.[46,51] Quantification was based on peptide response ratios, wherein the area of each
201 endogenous peptide was divided by that of its corresponding SIS.
202
203 *Discovery and verification of risk predictors*

204 Proteins for classifier model building were prefiltered using analytical performance criteria, including
205 mass spectrometry peak area cutoffs, coefficients of variance from replicate quality control samples,
206 and preanalytic stability. Models included one novel two-protein ratio and a composite clinical variable.
207 Based on strong predictive performance in nulliparas during discovery, the log ratio of insulin-like
208 growth factor-binding protein 4 (IBP4) to sex hormone-binding globulin (SHBG) was also included in
209 models as a second two-protein ratio unless SHBG was part of the novel ratio. Models were ranked in
210 discovery by a combination of area under the receiver operating characteristic curve (AUC) and
211 correlation with GAD amongst preeclamptic subjects, then filtered further for specificity at 75%
212 sensitivity in all subjects and nulliparas. Based on discovery performance, three clinical factors specified
213 in practice guidelines,[8,15,52-55] previous PE, pre-existing hypertension, and pregestational diabetes, were
214 combined into one variable (Clin3), deemed positive if any was true. This simple, fixed approach reduced
215 overfitting, leveraged prior biomarker knowledge, and produced classifiers that followed two model
216 structures:

217 1. log(IBP4/SHBG) + Clin3 + log(X/Y) or
218 2. Clin3 + log (X/SHBG)

219 where X and Y are protein analytes.
220
221 *Analysis*
222 Prevalence was calculated on the TREETOP validation cohort and aligned with the broader U.S.
223 population, as represented by National Vital Statistics System (NVSS) reporting[56] and Lisonkova et al.
224 (2013)[11] (e.g., for PE <34 weeks: TREETOP, 1.13%; Lisonkova, 1.24%; *P*=0.78).
225
226 Analyses followed prespecified protocols. Laboratory personnel and statisticians were blinded to clinical
227 data. Data linked to classifier scores were analyzed by an independent third-party statistician. Type I

228 error was controlled by fixed sequence hypothesis testing.[57,58] The sample size of the validation sub-
229 cohort was shown to have 84% power at 5% alpha to detect by Fisher's exact test an enrichment of
230 spontaneous PTB cases above a predictor score threshold associated with two-fold increased risk.[59] For
231 the purpose of validating preterm PE classifiers, this sub-cohort was estimated to show >90% power at
232 5% alpha to detect by regression test a significant enrichment above a 75% sensitivity threshold. At such
233 a threshold, the sub-cohort sample size was estimated to produce a 95% CI width for sensitivity of <25%
234 and for specificity of <5%.

235 All statistical tests were 2-tailed, unless specified, at significance <0.05 and performed in R
236 v3.5.1 or higher.[60] Count differences in categorical variables were assessed using the chi-squared test,
237 and median differences in continuous variables were assessed with the Wilcoxon test.[61] Comparison
238 across cohorts was performed using the Kruskal-Wallis test. Overall predictive performance was
239 assessed via AUC with direction of effect prespecified, significance assessed with a 1-sided Wilcoxon
240 test, and confidence intervals (CI) calculated using DeLong's method.[62] Clinical validity was assessed
241 using predictive performance and statistically significant stratification of preterm PE subjects above vs
242 below threshold scores. Following validation, sensitivity, specificity, PPV, NPV, SPR, likelihood ratios
243 (LR+, LR-), and odds ratios (OR) were calculated. Calculation of prevalence-dependent predictor
244 performance used the prevalence of the analysed outcome in the TREETOP-based validation cohort,
245 subset by early GA dating.

246

247 **Results**

248 Characteristics of the discovery, verification, and validation cohorts are summarized in **Table 1**. The
249 proportion of PE across all GAs ranged from 7.0%-7.7%, similar to the U.S. population prevalence. As
250 expected, subjects delivering with preterm PE were more likely than controls to have higher BMI, prior
251 PE, chronic hypertension, pregestational diabetes, and longer neonatal hospital stays.

252 No significant differences were seen across cohorts for chronic hypertension and pregestational
253 diabetes, but prior PE was increased among validation cohort controls (**Table 2**). Significant differences
254 were seen among cohorts in race, ethnicity, parity, educational attainment, maternal age, BMI, and
255 GAD. Maternal age and BMI did not contribute independently to preterm PE risk by regression. The
256 GABD difference reflected the broader collection window in the discovery cohort.

257 Nine of nine classifiers developed in discovery showed acceptable predictive performance in
258 verification, using a threshold of 75% sensitivity for preterm PE with GAD <37 weeks. In validation, all
259 nine exhibited significant AUCs (0.72-0.78) for preterm PE prediction, significant stratification for
260 preterm PE at three threshold scores, and significant Pearson correlations between predictor score and
261 GAD in PE subjects (**Supplemental Table 1**). Clin3 alone exhibited an AUC of 0.68 for preterm PE, falling
262 below the lower 95% CI of most classifiers.

263 **Figure 2** shows ROC curves for the predictor with the largest AUC (0.78), Clin3 + inhibin beta c
264 chain [INHBC]/SHBG) in the full validation cohort for all parity (A) and nulliparas (B). **Table 3** details its
265 performance in various testing scenarios for validation cohort subjects with early GA dating, and
266 **Supplemental Table 2** shows its performance in the full validation cohort. In the early GA dating sub-
267 cohort, sensitivity and specificity for predicting preterm PE (GAD <37 weeks) were 76% and 75%,
268 respectively. For early preterm PE (GAD <34 weeks), sensitivity increased (89%) with specificity
269 unchanged (75%), while using a GAD cutoff of <32 weeks improved specificity (98%) with sensitivity at
270 50%. Restricting the analysis to nulliparas resulted in a slightly lower sensitivity (75%) and higher
271 specificity (83%) at the <34-week cutoff. NPV under all clinical testing scenarios ranged from 98-100%.
272 PPVs ranged from 4-18%, depending on the outcome predicted and the population, consistent with the
273 low prevalence of these conditions in all cohorts. The ORs ranged from approximately 10 to almost 60,
274 demonstrating large increases in relative risk over background risk. Performance in the full validation
275 cohort was strong but slightly decreased for certain performance metrics (**Supplemental Table 2**).

276

277 **Structured Discussion/Comment**

278 *Principal findings*

279 Nine classifier models predictive of preterm PE risk were validated, with the Clin3 + INHBC/SHBG

280 predictor showing the best overall performance.

281

282 *Results*

283 Requiring simplicity (one or two bivariate protein biomarkers and a composite clinical variable)

284 and using large, diverse, and temporally divergent cohorts mitigated overfitting and enabled validation

285 in an independent population. Three clinical features that differed significantly between cases and

286 controls in the discovery cohort (prior PE, pre-existing hypertension, and pregestational diabetes)

287 comprised the composite clinical variable. A fourth, BMI, was excluded as it did not contribute

288 independently to preterm PE risk, perhaps due to strong associations between BMI and both diabetes

289 and SHBG.[63,64] Emphasizing strong predictive performance in both nulliparous and multiparous

290 pregnancies during discovery ensures broad applicability. In the two source cohorts, Black (17.8–19.0%)

291 and Hispanic (37.3– 41.2%) subjects were represented at proportions higher than those in the general

292 U.S. birthing population (14.1-15.2% Black; 23.7-24.2% Hispanic).[56,65]

293 Inhibin and activin, members of the transforming growth factor beta (TGFβ) family, are

294 dysregulated in pregnancy disorders. Elevated maternal serum Inhibin A was first reported as a

295 biomarker of fetal aneuploidy[66] but is also associated with PE,[67,68] including preclinical PE.[69] However,

296 Inhibin A, alone or in combination with other aneuploidy and fetal anomaly biomarkers, demonstrates

297 insufficient predictive performance for clinical use.[70,71] INHBC, a less well-characterized inhibin family

298 member comprised of activin C homodimers, was recently reported to function through activin

299 receptor-like kinase 7 (ALK7), which participates in angiogenesis, cytokine activity, pituitary and gonadal

300 hormone signaling, and embryonic development.[72] Expressed in villous and extravillous trophoblasts,
301 ALK7 is dysregulated in placentas from patients with PE[73] and is a mediator of hypoxia-induced
302 impairment of trophoblast invasion.[74] A potential role for INHBC in extravillous trophoblast
303 development and function may help explain its predictive value for preterm PE (**Figure 3**).
304 SHBG regulates biologically-active free steroid hormone levels,[75] increases up to 10-fold in the
305 maternal circulation during pregnancy, and is expressed by placental trophoblasts.[76-78] SHBG
306 transcription is suppressed by pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-
307 α),[79] which is relevant because inflammation, along with increased placental[80] and circulating[80,81] TNF-α,
308 is associated with PE (**Figure 3**). Dysregulation of maternal circulating SHBG in PE has been reported by
309 some[82] and disputed by others[76,77,83-85], perhaps due to variability in PE phenotype and GABD among
310 studies. Even in studies associating SHBG with PE, its predictive performance is poor.[82] In non-pregnant
311 adults, low serum SHBG has been associated with insulin resistance,[86] Type 2 diabetes,[87] and endothelial
312 dysfunction.[88] In one study, gravidas with low first-trimester SHBG and PlGF were at highest risk of
313 developing PE, leading authors to conclude that dysregulated angiogenesis and insulin resistance
314 exerted additive effects on PE risk.[86] Similarly, these results suggest that SHBG is an independent PE
315 predictor due to potential effects on insulin resistance and endothelial function, and predictive
316 performance improves markedly when combined with an angiogenic factor such as INHBC.
317
318 *Clinical implications*
319 Since these predictors allow for early risk assessments of multiple outcomes (PE with GAD <37,
320 <34, and <32 weeks) for a given pregnancy and account for parity, they enable individualized clinical
321 management. Patients identified as low risk can safely avoid unnecessary interventions. High-risk
322 patients can be assigned to increased surveillance for early detection of PE and associated
323 complications.

324 As exemplified with Clin3 + INHBC/SHBG, these predictors provide excellent stratification of
325 subjects at elevated risk for early-onset PE (<34 weeks), an outcome with a large clinical burden and
326 unmet need. Historically, 34 weeks has been an important GA landmark for PE, as ACOG recommends
327 delivery ≥34 weeks and expectant management with close observation for those below this GA.[8] Clark
328 et al. (2023)[89] recently recommended changes to classification of different PE subtypes to better reflect
329 the type and degree of associated organ dysfunction. We acknowledge that, if adopted, such
330 recommendations may alter clinical decision-making relevant to timing of delivery for PE. In addition,
331 new interventions for prevention or treatment may be discovered. Any of these developments may
332 require us to reassess predictor performance in the appropriate contexts. In regard to a more
333 immediate scenario, determining whether the predictors will be useful for decision-making regarding
334 LDASA prophylaxis requires more study, to establish LDASA efficacy among patients for whom guideline
335 criteria and the predictors produce discordant risk assessments.
336 Clinical practice guidelines include expectations for test performance, including high PPV, to
337 limit overtreatment.[8] However, PPV is impacted by a condition's prevalence. This study validated
338 predictive algorithms for a clinically important yet low-prevalence PE phenotype –
339 preterm PE in a cohort with a PE rate similar to the overall U.S. prevalence. This contrasts with a recent
340 study[90] that interrogated PE at any GA in a high-risk population (PE rate of 13.6%). Importantly,
341 according to the current standard of care, PE risk is assessed using a range of clinical algorithms, all of
342 which are inferior to the predictors validated in this study, with PPVs of 5.4% (NICE) and 5.6% (ACOG),
343 despite the use of an outcome with higher prevalence and lower clinical relevance (PE at any GA)[14].
344
345 *Research implications*
346 These predictors can be used to select high-risk pregnancies for interventional studies of prophylactic or
347 therapeutic agents. Determining whether preventive or therapeutic interventions alter maternal

348 biomarker levels is also of interest. Clinical application of a screening test is a two-step process: The first
349 step, reported here, is validation of predictive ability. The second, demonstrating clinical utility – i.e.,
350 improved outcomes, cost effectiveness, and ease of implementation – requires additional work.
351
352 *Strengths and limitations*
353 Strengths include the large, diverse, and temporally distinct datasets used for discovery, verification,
354 and validation. The composite clinical variable uses readily ascertained factors, and biomarkers were
355 prefiltered for excellent performance in ambient temperature sample transport conditions. These
356 properties support practicality for clinical use. Limitations include the modest number of early preterm
357 PE cases due to low prevalence and a mid-second-trimester blood draw that might not align optimally
358 with intervention timing.
359
360 *Conclusions*
361 Nine mid-trimester preterm PE risk predictors, designed to assess both proteomic biomarkers and
362 clinical risk factors from 18-20 weeks' gestation, demonstrated predictive ability superior to clinical
363 factors alone. The Clin3 + INHBC/SHBG predictor includes biomarkers with functional relevance to
364 pregnancy. All show promise for detecting risk of PE <34 weeks' GA and identifying pre-symptomatic
365 individuals who can benefit from increased surveillance, LDASA prophylaxis, and future therapies.
366
367 **Author contributions**
368 Conceptualization: TJG, JJB, PEK; data curation: ACF, ADP, MBB, TCF; formal analysis: LCL, ADP, MBB;
369 funding acquisition: JJB, PEK; investigation: LCL, GRS, GRM, KDH, CNS, JKB, SAL, LMP, EJS, MKH,ACF, TCF;
370 methodology: ACF, TCF, TJG. JJB, PEK; project administration: JJB, PEK; resources: LCL, GRS, GRM, KDH,
371 CNS, JKB, SAL, LMP, MKH, JJB, PEK; supervision: JJB, PEK; validation: JJB, PEK; visualization: LCL, JJB, PEK;

372 writing – original draft: LCL, JJB, PEK; writing – review and editing: all authors. All authors have read and
373 agreed to the published version of the manuscript.
374

375 **Acknowledgments**
376 The authors wish to acknowledge the following co-investigators on the original PAPR and/or TREETOP
377 studies: Kim A. Boggess, MD (University of North Carolina School of Medicine); Dean V. Coonrod, MD
378 (University of Arizona College of Medicine); Larry M. Cousins, MD (San Diego Perinatal Center; Rady
379 Children's Specialists of San Diego); Amy H. Crockett, MD (University of South Carolina School of
380 Medicine Greenville and Prisma Health-Upstate); M. Sean Esplin, MD (Intermountain Healthcare);
381 William A. Grobman, MD, MBA (The Ohio State University Wexner Medical Center); David M. Haas, MD
382 (Indiana University School of Medicine); Angela F. Hawk, MD (Regional Obstetrical Consultants); Jay D.
383 Iams, MD (The Ohio State University Wexner Medical Center); Carol A. Major, MD (University of
384 California Irvine School of Medicine); Scott A. Sullivan, MD (Medical University of South Carolina); and
385 Sarahn M. Wheeler, MD (Duke University School of Medicine). The authors also thank the study
386 coordinators and research personnel at the study sites, the clinical study participants, and the Sera
387 Prognostics, Inc. research and development, clinical laboratory and clinical operations teams. Babak
388 Shahbaba, PhD (University of California Irvine), conducted independent validation hypothesis testing.
389 Jennifer Logan, PhD (Sera Prognostics, Inc.), contributed to the writing of this article.
390

391 **Ethics statement**
392 The ethics committees/IRBs of all institutions participating in the original published studies upon which
393 this work is based gave ethical approval for this work. The following is a listing of PAPR (NCT01371019)
394 IRBs: IRB Intermountain Healthcare; IRB for Human Research, Medical University of South Carolina; IRB
395 The University of North Carolina at Chapel Hill; IRB Maricopa Integrated Health System; IRB Baystate

396 Medical Center; IRB Oregon Health & Science University; IRB University of Texas Medical Branch; IRB
397 Christiana Care; WCG IRB (previously Western IRB, used by The Ohio State University, San Diego
398 Perinatal Center, and Regional Obstetrical Consultants). The following is a listing of TREETOP
399 (NCT02787213) IRBs: IRB for Human Research, Medical University of South Carolina; IRB The University
400 of North Carolina at Chapel Hill; IRB Maricopa Integrated Health System; IRB Oregon Health & Science
401 University; IRB University of Texas Medical Branch; IRB Boston Medical Center; IRB Ochsner Clinic
402 Foundation; IRB University of California San Diego; Human Research Protections Program Northwestern
403 University; IRB Indiana University; IRB Duke Medicine; IRB for Clinical Investigations, Greenville Health
404 System; WCG IRB (previously Western IRB, used by Denver Health & Hospital Authority, University of
405 Colorado-Denver, UC-Irvine, Thomas Jefferson University, Regional Obstetrical Consultants, and
406 Baystate Medical Center).

407 **Glossary**

408 BMI, body mass index

409 CI, confidence interval

410 Early preterm PE, preeclampsia diagnosed with GAD<34 weeks

411 GA, gestational age

412 GAD, gestational age at delivery

413 IBP4, insulin-like growth factor-binding protein 4

414 INHBC, inhibin subunit beta c

415 IQR, interquartile range

416 LDASA, low-dose aspirin (acetylsalicylic acid)

417 LR, likelihood ratio

418 NPV, negative predictive value

419 PE, preeclampsia

420 Preterm PE, preeclampsia diagnosed with GAD <37 weeks

421 PPV, positive predictive value

422 PTB, preterm birth

423 SHBG, sex hormone-binding globulin

424 SPR, screen positive rate

425 TGFβ, transforming growth factor beta

426 TNFα, tumor necrosis factor-alpha

427 **References**

428 1. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and
429 Perspectives. *Circ Res*. Mar 29 2019;124(7):1094-1112. doi:10.1161/CIRCRESAHA.118.313276

430 2. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the
431 United States. *Obstet Gynecol*. Jun 2009;113(6):1299-1306. doi:10.1097/AOG.0b013e3181a45b25

432 3. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis.
433 *Lancet Glob Health*. Jun 2014;2(6):e323-33. doi:10.1016/S2214-109X(14)70227-X

434 4. Vogel JP, Souza JP, Mori R, et al. Maternal complications and perinatal mortality: findings of the
435 World Health Organization Multicountry Survey on Maternal and Newborn Health. *BJOG*. Mar 2014;121
436 Suppl 1:76-88. doi:10.1111/1471-0528.12633

437 5. Ngoc NT, Merialdi M, Abdel-Aleem H, et al. Causes of stillbirths and early neonatal deaths: data
438 from 7993 pregnancies in six developing countries. *Bull World Health Organ*. Sep 2006;84(9):699-705.
439 doi:10.2471/blt.05.027300

440 6. Ananth CV, Vintzileos AM. Medically indicated preterm birth: recognizing the importance of the
441 problem. *Clin Perinatol*. Mar 2008;35(1):53-67, viii. doi:10.1016/j.clp.2007.11.001

442 7. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-
443 Obstetrics. Chronic Hypertension in Pregnancy: ACOG Practice Bulletin No. 203. *Obstet Gynecol*. Jan
444 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020

445 8. American College of Obstetricians and Gynecologists. Gestational Hypertension and
446 Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol*. Jun 2020;135(6):e237-e260.
447 doi:10.1097/AOG.0000000000003891

448 9. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent
449 Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for

450 the US Preventive Services Task Force. *JAMA*. Sep 28 2021;326(12):1192-1206.
451 doi:10.1001/jama.2021.8551
452 10. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 203: Chronic
453 Hypertension in Pregnancy. *Obstet Gynecol*. Jan 2019;133(1):e26-e50.
454 doi:10.1097/aog.0000000000003020
455 11. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with
456 early- versus late-onset disease. *Am J Obstet Gynecol*. Dec 2013;209(6):544 e1-544 e12.
457 doi:10.1016/j.ajog.2013.08.019
458 12. Hao J, Hassen D, Hao Q, et al. Maternal and Infant Health Care Costs Related to Preeclampsia.
459 *Obstet Gynecol*. Dec 2019;134(6):1227-1233. doi:10.1097/AOG.0000000000003581
460 13. Stevens W, Shih T, Incerti D, et al. Short-term costs of preeclampsia to the United States health
461 care system. *Am J Obstet Gynecol*. Sep 2017;217(3):237-248 e16. doi:10.1016/j.ajog.2017.04.032
462 14. Rode L, Ekelund CK, Riishede I, Rasmussen S, Lidegaard O, Tabor A. Prediction of preterm pre-
463 eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to
464 2017. *Ultrasound Obstet Gynecol*. Oct 2021;58(4):561-567. doi:10.1002/uog.23693
465 15. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis
466 and management (NICE Guideline, NG 133). Accessed November 22, 2022,
467 https://www.ncbi.nlm.nih.gov/books/NBK546004/
468 16. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-
469 Obstetrics. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, No. 202: . *Obstet*
470 *Gynecol*. Jan 2019;133(1):1. doi:10.1097/AOG.0000000000003018
471 17. Acar N, Ustunel I. Expression of 52-kDa FK506-binding protein (FKBP52) in human placenta
472 complicated by preeclampsia and intrauterine growth restriction. *Anal Quant Cytopathol Histpathol*. Apr
473 2015;37(2):87-95.

474 18. Anand S, Bench Alvarez TM, Johnson WE, Esplin MS, Merrell K, Porter TF, Graves SW. Serum
475 biomarkers predictive of pre-eclampsia. *Biomark Med*. 2015;9(6):563-75. doi:10.2217/bmm.15.21
476 19. Bahado-Singh RO, Syngelaki A, Akolekar R, et al. Validation of metabolomic models for
477 prediction of early-onset preeclampsia. *Am J Obstet Gynecol*. Oct 2015;213(4):530 e1-530 e10.
478 doi:10.1016/j.ajog.2015.06.044
479 20. Garces MF, Sanchez E, Cardona LF, et al. Maternal Serum Meteorin Levels and the Risk of
480 Preeclampsia. *PLoS One*. 2015;10(6):e0131013. doi:10.1371/journal.pone.0131013
481 21. Karakus S, Bozoklu Akkar O, Yildiz C, Sancakdar E, Cetin M, Cetin A. Serum levels of ET-1, M30,
482 and angiopoietins-1 and -2 in HELLP syndrome and preeclampsia compared to controls. *Arch Gynecol*
483 *Obstet*. Feb 2016;293(2):351-9. doi:10.1007/s00404-015-3803-1
484 22. Koster MP, Vreeken RJ, Harms AC, et al. First-Trimester Serum Acylcarnitine Levels to Predict
485 Preeclampsia: A Metabolomics Approach. *Dis Markers*. 2015;2015:857108. doi:10.1155/2015/857108
486 23. Salvianti F, Inversetti A, Smid M, et al. Prospective evaluation of RASSF1A cell-free DNA as a
487 biomarker of pre-eclampsia. *Placenta*. Sep 2015;36(9):996-1001. doi:10.1016/j.placenta.2015.07.003
488 24. Teoh SS, Zhao M, Wang Y, Chen Q, Nie G. Serum HtrA1 is differentially regulated between early-
489 onset and late-onset preeclampsia. *Placenta*. Sep 2015;36(9):990-5. doi:10.1016/j.placenta.2015.07.001
490 25. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1)
491 may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest*.
492 Mar 2003;111(5):649-58. doi:10.1172/JCI17189
493 26. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia.
494 *N Engl J Med*. Feb 12 2004;350(7):672-83. doi:10.1056/NEJMoa031884
495 27. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta
496 subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with

497 obstetric complications: a population-based screening study (the FASTER Trial). *Am J Obstet Gynecol*. Oct
498 2004;191(4):1446-51. doi:10.1016/j.ajog.2004.06.052
499 28. Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy
500 outcome. *Obstet Gynecol*. Aug 2005;106(2):260-7. doi:10.1097/01.AOG.0000172419.37410.eb
501 29. Srinivasan S, Treacy R, Herrero T, et al. Discovery and Verification of Extracellular miRNA
502 Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women. *Cell Rep Med*. May
503 19 2020;1(2)doi:10.1016/j.xcrm.2020.100013
504 30. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with
505 Suspected Preeclampsia. *N Engl J Med*. Jan 7 2016;374(1):13-22. doi:10.1056/NEJMoa1414838
506 31. Cerdeira AS, O'Sullivan J, Ohuma EO, et al. Randomized Interventional Study on Prediction of
507 Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE. *Hypertension*. Oct
508 2019;74(4):983-990. doi:10.1161/HYPERTENSIONAHA.119.12739
509 32. Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with
510 suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
511 *Lancet*. May 4 2019;393(10183):1807-1818. doi:10.1016/S0140-6736(18)33212-4
512 33. McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH. Comparison of three
513 commercially available placental growth factor-based tests in women with suspected preterm pre-
514 eclampsia: the COMPARE study. *Ultrasound Obstet Gynecol*. Jan 2019;53(1):62-67.
515 doi:10.1002/uog.19051
516 34. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the
517 prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am J
518 Obstet Gynecol*. Feb 2017;216(2):110-120 e6. doi:10.1016/j.ajog.2016.09.076

519 35. Di Lorenzo G, Ceccarello M, Cecotti V, et al. First trimester maternal serum PIGF, free beta-hCG,
520 PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. *Placenta*.
521 Jun 2012;33(6):495-501. doi:10.1016/j.placenta.2012.03.003
522 36. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined Screening for Preeclampsia and
523 Small for Gestational Age at 11-13 Weeks. *Fetal Diagn Ther*. Sep 13 2012;doi:000341712 [pii]
524 10.1159/000341712
525 37. Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH. Prediction of small for gestational age
526 neonates: screening by biophysical and biochemical markers at 19-24 weeks. *Ultrasound in obstetrics &*
527 *gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*.
528 May 18 2015;doi:10.1002/uog.14904
529 38. Lesmes C, Gallo DM, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age
530 neonates: screening by maternal serum biochemical markers at 19-24 weeks. *Ultrasound in obstetrics &*
531 *gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*.
532 May 13 2015;doi:10.1002/uog.14899
533 39. Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. Unsupervised Placental
534 Gene Expression Profiling Identifies Clinically Relevant Subclasses of Human Preeclampsia. *Hypertension*.
535 Jul 2016;68(1):137-47. doi:10.1161/HYPERTENSIONAHA.116.07293
536 40. Leavey K, Bainbridge SA, Cox BJ. Large scale aggregate microarray analysis reveals three distinct
537 molecular subclasses of human preeclampsia. *PLoS One*. 2015;10(2):e0116508.
538 doi:10.1371/journal.pone.0116508
539 41. Thomsen LC, Melton PE, Tollaksen K, et al. Refined phenotyping identifies links between
540 preeclampsia and related diseases in a Norwegian preeclampsia family cohort. *J Hypertens*. Nov
541 2015;33(11):2294-302. doi:10.1097/HJH.0000000000000696

542 42. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, Global Pregnancy C. Subtypes of
543 Preeclampsia: Recognition and Determining Clinical Usefulness. *Hypertension*. May 5 2021;77(5):1430-
544 1441. doi:10.1161/HYPERTENSIONAHA.120.14781
545 43. Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology
546 of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to
547 late-onset preeclampsia. *Am J Obstet Gynecol*. Feb 2022;226(2S):S867-S875.
548 doi:10.1016/j.ajog.2021.11.019
549 44. Masini G, Foo LF, Tay J, Wilkinson IB, Valensise H, Gyselaers W, Lees CC. Preeclampsia has two
550 phenotypes which require different treatment strategies. *Am J Obstet Gynecol*. Feb 2022;226(2S):S1006-
551 S1018. doi:10.1016/j.ajog.2020.10.052
552 45. Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical
553 Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine. In: Micheel
554 CM, Nass SJ, Omenn GS, eds. *Evolution of Translational Omics: Lessons Learned and the Path Forward*.
555 National Academies Press (US)
556 Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2012.
557 46. Saade GR, Boggess KA, Sullivan SA, et al. Development and validation of a spontaneous preterm
558 delivery predictor in asymptomatic women. *Am J Obstet Gynecol*. May 2016;214(5):633 e1-633 e24.
559 doi:10.1016/j.ajog.2016.02.001
560 47. Markenson GR, Saade GR, Laurent LC, et al. Performance of a proteomic preterm delivery
561 predictor in a large independent prospective cohort. *Am J Obstet Gynecol MFM*. Aug 2020;2(3):100140.
562 doi:10.1016/j.ajogmf.2020.100140
563 48. American College of Obstetricians and Gynecologists. Committee Opinion No 611: Methods for
564 Estimating Due Date. *Obstet Gynecol*. Oct 2014;124(4):863-866.
565 doi:10.1097/01.AOG.0000454932.15177.be

566 49. American College of Obstetricians and Gynecologists. Committee Opinion No 700: Methods for
567 Estimating the Due Date. *Obstet Gynecol*. May 2017;129(5):e150-e154.
568 doi:10.1097/AOG.0000000000002046
569 50. Burchard J, Saade GR, Boggess KA, et al. Better Estimation of Spontaneous Preterm Birth
570 Prediction Performance through Improved Gestational Age Dating. *J Clin Med*. May 19
571 2022;11(10)doi:10.3390/jcm11102885
572 51. Bradford C, Severinsen R, Pugmire T, et al. Analytical validation of protein biomarkers for risk of
573 spontaneous preterm birth. *Clinical Mass Spectrometry*. 2017/01/01/ 2017;3:25-38.
574 doi:10.1016/j.clinms.2017.06.002
575 52. Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive
576 disorders of pregnancy 2014. *Aust N Z J Obstet Gynaecol*. Oct 2015;55(5):e1-29. doi:10.1111/ajo.12399
577 53. Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy:
578 Diagnosis, Prediction, Prevention, and Management. *J Obstet Gynaecol Can*. May 2022;44(5):547-571
579 e1. doi:10.1016/j.jogc.2022.03.002
580 54. World Health Organization. *WHO Recommendations for Prevention and Treatment of Pre-*
581 *Eclampsia and Eclampsia.* Geneva: World Health Organization; 2011.
582 55. Brown MA, Magee LA, Kenny LC, et al. Hypertensive Disorders of Pregnancy: ISSHP
583 Classification, Diagnosis, and Management Recommendations for International Practice. *Hypertension*.
584 Jul 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803
585 56. Osterman MJK, Hamilton BE, Martin, J.A., Driscoll AKV, C.P. Births: Final Data for 2020. Division
586 of Vital Statistics, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention.
587 Updated 2022 Feb 7. Accessed cited 2022 Feb 9, https://www.cdc.gov/nchs/nvss/births.htm
588 57. Dmitrienko A, Tamhane A, Bretz F, eds. *Multiple Testing Problems in Pharmaceutical Statistics*.
589 CRC Press; 2009.

590 58. Dmitrienko A, D'Agostino RB, Sr., Huque MF. Key multiplicity issues in clinical drug development.
591 *Stat Med*. Mar 30 2013;32(7):1079-111. doi:10.1002/sim.5642
592 59. Burchard J, Polpitiya AD, Fox AC, et al. Clinical Validation of a Proteomic Biomarker Threshold for
593 Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study. *J*
594 *Clin Med*. Oct 29 2021;10(21):5088. doi:10.3390/jcm10215088
595 60. R Foundation. The R Project for Statistical Computing. Accessed August 1, 2022, https://www.r-
596 project.org/
597 61. Yoshida K, Bartel A. tableone: Create 'Table 1' to Describe Baseline Characteristics with or
598 without Propensity Score Weights; R package version 0.13.2. Accessed November 21, 2022,
599 https://cran.r-project.org/web/packages/tableone/index.html
600 62. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
601 receiver operating characteristic curves: a nonparametric approach. *Biometrics*. Sep 1988;44(3):837-45.
602 63. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM. The association of obesity with sex
603 hormone-binding globulin is stronger than the association with ageing--implications for the
604 interpretation of total testosterone measurements. *Clin Endocrinol (Oxf)*. Dec 2015;83(6):828-33.
605 doi:10.1111/cen.12768
606 64. Birkebaek NH, Lange A, Holland-Fischer P, et al. Effect of weight reduction on insulin sensitivity,
607 sex hormone-binding globulin, sex hormones and gonadotrophins in obese children. *Eur J Endocrinol*.
608 Dec 2010;163(6):895-900. doi:10.1530/EJE-10-0538
609 65. March of Dimes Peristats. Births. Accessed July 1, 2023,
610 https://www.marchofdimes.org/peristats/data?reg=99&top=2&stop=10&lev=1&slev=1&obj=3
611 66. Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down's syndrome in
612 early pregnancy. *N Engl J Med*. May 9 1996;334(19):1231-6. doi:10.1056/NEJM199605093341904

613 67. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as
614 possible endocrine markers for pre-eclampsia. *Lancet*. May 3 1997;349(9061):1285-8.
615 doi:10.1016/s0140-6736(96)09264-1
616 68. Fraser RF, 2nd, McAsey ME, Coney P. Inhibin-A and pro-alpha C are elevated in preeclamptic
617 pregnancy and correlate with human chorionic gonadotropin. *Am J Reprod Immunol*. Jul 1998;40(1):37-
618 42. doi:10.1111/j.1600-0897.1998.tb00386.x
619 69. Muttukrishna S, North RA, Morris J, et al. Serum inhibin A and activin A are elevated prior to the
620 onset of pre-eclampsia. *Hum Reprod*. Jul 2000;15(7):1640-5. doi:10.1093/humrep/15.7.1640
621 70. Morris RK, Cnossen JS, Langejans M, et al. Serum screening with Down's syndrome markers to
622 predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. *BMC*
623 *Pregnancy Childbirth*. Aug 4 2008;8:33. doi:10.1186/1471-2393-8-33
624 71. Huang T, Bedford HM, Rashid S, et al. Modified multiple marker aneuploidy screening as a
625 primary screening test for preeclampsia. *BMC Pregnancy Childbirth*. Mar 8 2022;22(1):190.
626 doi:10.1186/s12884-022-04514-4
627 72. Goebel EJ, Ongaro L, Kappes EC, et al. The orphan ligand, activin C, signals through activin
628 receptor-like kinase 7. *Elife*. Jun 23 2022;11doi:10.7554/eLife.78197
629 73. Nadeem L, Munir S, Fu G, et al. Nodal signals through activin receptor-like kinase 7 to inhibit
630 trophoblast migration and invasion: implication in the pathogenesis of preeclampsia. *Am J Pathol*. Mar
631 2011;178(3):1177-89. doi:10.1016/j.ajpath.2010.11.066
632 74. Hu M, Wang Y, Meng Y, et al. Hypoxia induced-disruption of lncRNA TUG1/PRC2 interaction
633 impairs human trophoblast invasion through epigenetically activating Nodal/ALK7 signalling. *J Cell Mol*
634 *Med*. Jul 2022;26(14):4087-4100. doi:10.1111/jcmm.17450
635 75. Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. *Biol Reprod*. Sep
636 2011;85(3):431-41. doi:10.1095/biolreprod.111.092593

637 76. Anderson DC. Sex-hormone-binding globulin. *Clin Endocrinol (Oxf)*. Jan 1974;3(1):69-96.
638 doi:10.1111/j.1365-2265.1974.tb03298.x
639 77. Sun L, Jin Z, Teng W, Chi X, Zhang Y, Ai W, Wang P. Expression changes of sex hormone binding
640 globulin in GDM placental tissues. *J Perinat Med*. Nov 19 2011;40(2):129-35. doi:10.1515/JPM.2011.128
641 78. Larrea F, Diaz L, Carino C, Larriva-Sahd J, Carrillo L, Orozco H, Ulloa-Aguirre A. Evidence that
642 human placenta is a site of sex hormone-binding globulin gene expression. *J Steroid Biochem Mol Biol*.
643 Oct 1993;46(4):497-505. doi:10.1016/0960-0760(93)90104-5
644 79. Simó R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM. Novel insights in SHBG
645 regulation and clinical implications. *Trends Endocrinol Metab*. Jul 2015;26(7):376-83.
646 doi:10.1016/j.tem.2015.05.001
647 80. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN, Jr., Bennett
648 WA. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin
649 10 is increased in preeclampsia. *Am J Obstet Gynecol*. Oct 1999;181(4):915-20. doi:10.1016/s0002-
650 9378(99)70325-x
651 81. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with
652 preeclampsia. *Am J Reprod Immunol*. Aug 1998;40(2):102-11. doi:10.1111/j.1600-0897.1998.tb00398.x
653 82. Yu CK, Papageorghiou AT, Bindra R, Spencer K, Nicolaides KH. Second-trimester sex hormone-
654 binding globulin and subsequent development of pre-eclampsia. *J Matern Fetal Neonatal Med*. Sep
655 2004;16(3):158-62. doi:10.1080/14767050400013297
656 83. Nevalainen J, Korpimaki T, Kouru H, Sairanen M, Ryynanen M. Performance of first trimester
657 biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia. *Metabolism*.
658 Oct 2017;75:6-15. doi:10.1016/j.metabol.2017.07.004

659 84. Sharifzadeh F, Kashanian M, Fatemi F. A comparison of serum androgens in pre-eclamptic and
660 normotensive pregnant women during the third trimester of pregnancy. *Gynecol Endocrinol*. Oct
661 2012;28(10):834-6. doi:10.3109/09513590.2012.683061
662 85. Tuutti EK, Hamalainen EK, Sainio SM, Hiilesmaa VK, Turpeinen UL, Alfthan HV, Stenman UH.
663 Serum testosterone levels during early pregnancy in patients developing preeclampsia. *Scand J Clin Lab*
664 *Invest*. Sep 2011;71(5):413-8. doi:10.3109/00365513.2011.580858
665 86. Thadhani R, Ecker JL, Mutter WP, et al. Insulin resistance and alterations in angiogenesis:
666 additive insults that may lead to preeclampsia. *Hypertension*. May 2004;43(5):988-92.
667 doi:10.1161/01.HYP.0000124460.67539.1d
668 87. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin
669 resistance. *Clin Endocrinol (Oxf)*. Mar 2013;78(3):321-9. doi:10.1111/cen.12086
670 88. Maggio M, Cattabiani C, Lauretani F, et al. SHBG and endothelial function in older subjects. *Int J*
671 *Cardiol*. Oct 3 2013;168(3):2825-30. doi:10.1016/j.ijcard.2013.03.083
672 89. Clark SL, Saade GA, Tolcher MC, et al. Gestational hypertension and "severe" disease: time for a
673 change. *Am J Obstet Gynecol*. May 2023;228(5):547-552. doi:10.1016/j.ajog.2022.11.1280
674 90. Rasmussen M, Reddy M, Nolan R, et al. RNA profiles reveal signatures of future health and
675 disease in pregnancy. *Nature*. Jan 2022;601(7893):422-427. doi:10.1038/s41586-021-04249-w
676

Table 1. Demographic and clinical characteristics of preterm preeclampsia (PE) cases and noncases in the discovery, verification, and validation cohorts.

	Discovery (PAPR)			Verification (TREETOP)			Validation (TREETOP)		
Cases and noncases	**Preterm PE <37 weeks' gestation**	**No PE or PE ≥37 weeks' gestation**	***P* value**	**Preterm PE <37 weeks' gestation**	**No PE or PE ≥37 weeks' gestation**	***P* value**	**Preterm PE <37 weeks' gestation**	**No PE or PE ≥37 weeks' gestation**	***P* value**
Number of subjects (n, %)	45 (3.3)	1307 (96.7)		34 (2.7)	1217 (97.3)		62 (2.7)	2227 (97.3)	
Maternal age (y)			0.586			0.640			0.705
Median	26	27		28.5	30		30	29	
IQR	24–31	23–32		27–32	25–33		25–34	25–33	
Unknown (n)	0	0		0	0		0	0	
BMI			0.003			0.027			<0.001
Median	29.6	26.6		28.3	26.1		30.9	25.8	
IQR	26.17–38.0	22.7–32.4		25.7–32.9	22.6–31.0		25.9–35.5	22.3–31.1	
Unknown (n)	1	23		1	14		1	25	
Maternal race (n, %)			0.114			0.838			0.579
Black	13 (28.9)	224 (17.1)		5 (14.7)	233 (19.1)		14 (22.6)	393 (17.6)	
White	29 (64.4)	952 (72.8)		21 (61.8)	757 (62.2)		34 (54.8)	1411 (63.4)	
Other	3 (6.7)	131 (10.0)		7 (20.6)	205 (16.8)		12 (19.4)	370 (16.6)	
Unknown (n)	0 (0.0)	0 (0.0)		1 (2.9)	22 (1.8)		2 (3.2)	53 (2.4)	
Maternal ethnicity (n, %)			0.180			0.104			0.243
Hispanic	12 (26.7)	492 (37.6)		20 (58.8)	495 (40.7)		30 (48.4)	895 (40.2)	
Non-Hispanic	33 (73.3)	815 (62.4)		14 (41.2)	720 (59.2)		32 (51.6)	1332 (59.8)	
Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	2 (0.2)		0 (0.0)	0 (0.0)	
Maternal education level (n, %)			0.131			0.329			0.194
No high school graduation	17 (37.8)	338 (25.9)		4 (11.8)	192 (15.8)		10 (16.1)	317 (14.2)	
High school degree/GED	21 (46.7)	635 (48.6)		21 (61.8)	558 (45.9)		35 (56.5)	1033 (46.4)	
College degree	6 (13.3)	323 (24.7)		9 (26.5)	463 (38.0)		16 (25.8)	861 (38.7)	
Unknown (n)	1 (2.2)	11 (0.8)		0 (0.0)	4 (0.3)		1 (1.6)	16 (0.7)	
Parity (n, %)			0.591			0.838			0.307
Nulliparous (*P*=0)	18 (40.0)	457 (35.0)		13 (38.2)	505 (41.5)		31 (50.0)	950 (42.7)	
Multiparous (*P*≥1)	27 (60.0)	850 (65.0)		21 (61.8)	712 (58.5)		31 (50.0)	1277 (57.3)	
Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Previous PE (preterm + term) (n, %)			<0.001			<0.001			<0.001
No	13 (48.1)	777 (91.4)		11 (52.4)	653 (91.7)		18 (58.1)	1102 (86.3)	
Yes	14 (51.9)	73 (8.6)		10 (47.6)	59 (8.3)		13 (41.9)	175 (13.7)	
Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Chronic hypertension (n, %)			<0.001			<0.001			<0.001
No	35 (77.8)	1229 (94.0)		26 (76.5)	1154 (94.8)		37 (59.7)	2124 (95.4)	
Yes	10 (22.2)	78 (6.0)		8 (23.5)	63 (5.2)		25 (40.3)	103 (4.6)	
Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Pregestational diabetes mellitus (n, %)			<0.001			0.001			<0.001

	No	31 (68.9)	1250 (95.6)		28 (82.4)	1166 (95.8)		47 (75.8)	2118 (95.1)	
	Yes	14 (31.1)	57 (4.4)		6 (17.6)	51 (4.2)		15 (24.2)	109 (4.9)	
	Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Gestational age at blood draw (d)				0.233			0.854			0.600
	Median	137	140		137	136		136.5	137	
	IQR	133–143	132–148		134–140	132–141		130–141	133–141	
	Unknown (n)	0	0		0	0		0	0	
Gestational age at delivery (d)				<0.001			<0.001			<0.001
	Median	248	274		243.5	275		240	275	
	IQR	236–254	267–279		224–253	269–281		226–252	270–280	
	Unknown (n)	0	0		0	0		0	0	
Neonatal length of hospital stay (d)				<0.001			<0.001			<0.001
	Median	5	3		13.5	2		11	2	
	IQR	3-13	2-3		6-28	2-3		4-28	2-3	
	Unknown (n)	0	12		0	6		2	7	
Neonatal gender (n, %)				0.920			0.809			0.676
	Female	23 (51.1)	643 (49.2)		15 (44.1)	603 (49.5)		34 (54.8)	1100 (49.4)	
	Male	22 (48.9)	664 (50.8)		19 (55.9)	613 (50.4)		28 (45.2)	1124 (50.5)	
	Ambiguous	0 (0.0)	0 (0.0)		0 (0.0)	1 (0.1)		0 (0.0)	3 (0.1)	
	Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	3 (0.1)	

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparisons between cases (PE <37 weeks' gestation) and noncases (no PE or PE ≥37 weeks' gestation) were performed using Wilcoxon or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR[46] and TREETOP[47] study protocols. BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

Table 2. Comparison of demographic and clinical characteristics across the discovery, verification, and validation cohorts.

		Discovery (PAPR)	Verification (TREETOP)	Validation (TREETOP)	*P* value
Number of subjects		1352	1251	2289	
Maternal age					<0.001
	Median	27	30	29	
	IQR	23–32	25–33	25–33	
	Unknown (n)	0	0	0	
BMI					0.005
	Median	26.6	26.3	26.0	
	IQR	22.7–32.6	22.6–31.0	22.3–31.2	
	Unknown (n)	24	15	26	
Maternal race (n, %)					<0.001
	Black	237 (17.5)	238 (19.0)	407 (17.8)	
	White	981 (72.6)	778 (62.2)	1445 (63.1)	
	Other	134 (9.9)	212 (16.9)	382 (16.7)	
	Unknown (n)	0 (0.0)	23 (1.8)	55 (2.4)	
Maternal ethnicity (n, %)					0.028
	Hispanic	504 (37.3)	515 (41.2)	925 (40.4)	
	Non-Hispanic	848 (62.7)	734 (58.7)	1364 (59.6)	
	Unknown (n)	0 (0.0)	2 (0.2)	0 (0.0)	
Maternal education level (n, %)					<0.001
	No high school graduation	355 (26.3)	196 (15.7)	327 (14.3)	
	High school degree/GED	656 (48.5)	579 (46.3)	1068 (46.7)	
	College degree	329 (24.3)	472 (37.7)	877 (38.3)	
	Unknown (n)	12 (0.9)	4 (0.3)	17 (0.7)	
Parity (n, %)					<0.001
	Nulliparous (*P*=0)	475 (35.1)	518 (41.4)	981 (42.9)	
	Multiparous (*P*≥1)	877 (64.9)	733 (58.6)	1308 (57.1)	
	Unknown	0 (0.0)	0 (0.0)	0 (0.0)	
Previous PE (preterm + term) (n, %)					<0.001
	No	790 (90.1)	664 (90.6)	1120 (85.6)	
	Yes	87 (9.9)	69 (9.4)	188 (14.4)	
	Unknown	0 (0.0)	0 (0.0)	0 (0.0)	
Chronic hypertension (n, %)					0.495
	No	1264 (93.5)	1180 (94.3)	2161 (94.4)	
	Yes	88 (6.5)	71 (5.7)	128 (5.6)	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Pregestational diabetes mellitus (n, %)					0.531
	No	1281 (94.7)	1194 (95.4)	2165 (94.6)	
	Yes	71 (5.3)	57 (4.6)	124 (5.4)	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at blood draw (d)					<0.001
	Median	140	136	137	
	IQR	132–147	132–141	133–141	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at delivery (d)					<0.001
	Median	273	275	274	
	IQR	266–278	268–281	269–280	
	Unknown (n)	0 (0.0)	0 (0.0)	0 (0.0)	
Neonatal length of hospital stay (d)					<0.001
	Median	3	2	2	
	IQR	2–3	2–3	2–3	
	Unknown (n)	12	6	9	
Neonatal gender (n, %)					0.384
	Female	666 (49.3)	618 (49.4)	1134 (49.5)	
	Male	686 (50.7)	632 (50.5)	1152 (50.3)	
	Ambiguous	0 (0.0)	1 (0.1)	0 (0.0)	
	Unknown	0 (0.0)	0 (0.0)	3 (0.1)	

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparison among the three cohorts was performed using Kruskal-

Wallis or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR[46] and TREETOP[47] study protocols.
BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

Table 3. Performance of the Clin3 + INHBC/SHBG classifier model for prediction of preterm preeclampsia by gestational age cutoff, risk score thresholds, and parity in the validation cohort restricted by early gestational age at ultrasound.

Cohort	Tested population	Preterm preeclampsia GA (weeks)	Cases/ Controls (%)	AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	SPR	LR+	LR-	OR
Validation cohort with early GA ultrasound	All parity	<37	29/883 (3.3)	0.82 (0.74 – 0.89)	76%	75%	9%	99%	26%	3.06	0.32	9.53
		<34	9/903 (1.0)	0.87 (0.80 – 0.93)	89%	75%	3%	100%	26%	3.54	0.15	23.82
		<32	4/908 (0.4)	0.89 (0.78 – 1.00)	50%	98%	12%	100%	2%	30.27	0.51	59.53
	Nulliparas	<37	15/361 (4.2)	0.81 (0.71 – 0.92)	53%	90%	8%	99%	12%	5.35	0.52	10.32
		<34	4/372 (1.1)	0.90 (0.81 – 0.98)	75%	83%	2%	100%	18%	4.29	0.30	14.17

CI, confidence interval; Clin3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; SHBG, sex hormone-binding globulin.

FIGURE LEGENDS

Figure 1. Distribution of subjects in the discovery, verification, and validation cohorts.



GA, gestational age.

Figure 2. Receiver operating characteristic performance for the preterm preeclampsia (PE) classifier Clin3 + INHBC/SHBG in the full validation cohort. The plots graph sensitivity (true positive rate) vs 1-specificity (false positive rate) for (A) all preterm PE cases with gestational age at delivery (GAD) <37 weeks, and (B) nulliparous subjects with preterm PE with GAD <37 and early preterm PE with GAD <34 weeks.



AUC, area under the receiver operating characteristic curve; CI, confidence interval; Clin3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; INHBC, inhibin subunit beta c; SHBG, sex hormone binding globulin.

Figure 3. Potential roles of INHBC and SHBG in placentation. (A) Activin C, a homodimer of INHBC, signals through the ALK7 receptor, which is itself dysregulated in preeclampsia. (B) SHBG expression has been demonstrated to be downregulated by pro-inflammatory cytokines in hepatocytes, and its extra-hepatic expression has been shown to include trophoblasts. (C) A model illustrating the association of INHBC, ALK7 and SHBG with abnormal placentation and aberrant spiral artery remodeling.



ActC, activin C, an INHBC homodimer; ACTRII, activin receptor type 2A; ALK7, activin A receptor type 1C; AMPK, AMP-activated protein kinase; c-Jun, Jun proto-oncogene, AP-1 transcription factor subunit; HNF-4α, hepatocyte nuclear factor 4 alpha; IκBα, NFκB inhibitor alpha; IL1β, interleukin 1 beta; IL1β, interleukin 1 beta receptor; INHBC, inhibin subunit beta c; JNK, mitogen-activated protein kinase 8; MEK1/2, mitogen-activated protein kinase kinases 1 and 2; MMP2/9, matrix metalloproteinases 2 and 9; NFκB, nuclear factor kappa B; SHBG, sex hormone binding globulin; SMAD2/3, SMAD family members 2 and 3; TIMP-1, TIMP metallopeptidase inhibitor 1; TNFα, tumor necrosis factor alpha; TNFRα, tumor necrosis factor alpha receptor.

SUPPLEMENTAL DATA

Supplemental Table 1. Summary of validation performance of each of the nine candidate classifier models. Score thresholds are specific to each classifier and differentiate subjects predicted to be at higher risk for preterm preeclampsia, defined as preeclampsia <37 weeks' gestation, from those predicted to be at lower risk. Three score thresholds were validated for each classifier to assess classification performance. The linear relationship between the gestational age at delivery and classifier prediction was assessed by the Pearson correlation coefficient. Validation performance is reported across the nine classifiers without protein specific batch calibration.

Classifier	AUC [95% CI]	1° threshold *P* value	2° threshold *P* value	3° threshold *P* value	Pearson correlation coefficient *r*	Pearson correlation coefficient *P* value
Clin3 + INHBC/SHBG	0.78 [0.73-0.84]	7.26×10^{-13}	2.69×10^{-12}	3.64×10^{-11}	-0.275	2.20×10^{-04}
Clin3 + IBP4/SHBG + AFAM/PRG2	0.77 [0.71-0.83]	4.13×10^{-12}	1.30×10^{-11}	2.26×10^{-11}	-0.29	1.19×10^{-04}
Clin3 + AFAM/SHBG	0.76 [0.69-0.82]	7.36×10^{-11}	7.46×10^{-11}	4.22×10^{-13}	-0.24	1.25×10^{-03}
Clin3 + CD14/SHBG	0.76 [0.70-0.82]	5.27×10^{-12}	1.24×10^{-10}	3.03×10^{-10}	-0.26	4.44×10^{-04}
Clin3 + IBP4/SHBG + AFAM/CSH†	0.76 [0.69-0.82]	6.04×10^{-12}	4.61×10^{-11}	4.22×10^{-11}	-0.25	9.17×10^{-04}
Clin3 + IBP4/SHBG + CD14/PRG2	0.76 [0.70-0.83]	4.61×10^{-11}	2.47×10^{-13}	1.25×10^{-11}	-0.29	7.53×10^{-05}
Clin3 + IBP4/SHBG + PEDF/CSH†	0.76 [0.70-0.82]	1.89×10^{-11}	1.63×10^{-11}	1.51×10^{-11}	-0.26	4.32×10^{-04}
Clin3 + IBP4/SHBG + PEDF/CBPN	0.73 [0.67-0.80]	1.20×10^{-11}	2.00×10^{-11}	4.22×10^{-10}	-0.24	1.16×10^{-03}
Clin3 + IBP4/SHBG + CD14/CBPN	0.72 [0.66-0.79]	1.60×10^{-10}	3.08×10^{-11}	1.28×10^{-10}	-0.25	9.96×10^{-04}

†Represents CSH1 and CSH2. The two proteins differ by one amino acid residue, which is not included in the peptide fragment measured by the predictor.

AFAM, afamin; AUC, area under the receiver operating characteristic curve; CBPN, carboxypeptidase N catalytic chain; CD14, monocyte differentiation antigen CD14; CI, confidence interval; Clin3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; CSH, chorionic somatomammotropin hormone 1/2; IBP4, insulin-like growth factor-binding protein 4; PEDF, pigment epithelium-derived factor; PRG2, bone marrow proteoglycan; SHBG, sex hormone-binding globulin.

Supplemental Table 2. Performance of the Clin3 + INHBC/SHBG classifier model for prediction of preterm preeclampsia by gestational age cutoff, risk score threshold, and parity in the full validation cohort.

Cohort	Tested population	Preterm preeclampsia GA (weeks)	Cases/Controls (%)	AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	SPR	LR+	LR-	OR
Full validation cohort	All parity	<37	62/2261 (2.7)	0.79 (0.74 – 0.85)	71%	74%	7%	99%	27%	2.77	0.39	7.10
		<34	26/2261 (1.1)	0.83 (0.78 – 0.89)	81%	74%	4%	100%	26%	3.14	0.26	12.13
		<32	12/2261 (0.5)	0.83 (0.73 – 0.93)	25%	98%	8%	100%	2%	15.62	0.76	20.49
	Nulliparas	<37	31/969 (3.1)	0.76 (0.68 – 0.85)	45%	88%	5%	99%	13%	3.7	0.62	6
		<34	13/969 (1.3)	0.81 (0.73 – 0.90)	62%	81%	3%	99%	20%	3.23	0.48	6.80

CI, confidence interval; Clin3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; SHBG, sex hormone-binding globulin.